HEAT BIOLOGICS
Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) adjuvant technology for use in a number of oncology and infectious disease indications. Heat’s ImPACT therapy is a first-in-class fully human adjuvant system that functions as both an immune stimulator and an antigen-delivery system. ImPACT is rapidly applied to a selected off-the-shelf cancer cell line to effectively transform living tumor into powerful machines... that “pump out” their full antigenic fingerprint to robustly stimulate the immune system against the targeted disease. ImPACT is applicable to a wide range of cancers as well as infectious diseases including HIV, HCV and malaria. Heat is currently in Phase II clinical trials with its first drug to treat Non Small Cell Lung Cancer (NSCLC) and plans to initiate clinical trials against additional cancers in 2012.
HEAT BIOLOGICS
Industry:
Biotechnology Health Care Medical
Founded:
2008-01-01
Address:
Chapel Hill, North Carolina, United States
Country:
United States
Website Url:
http://www.heatbio.com
Total Employee:
11+
Status:
Active
Contact:
9192407540
Total Funding:
50.08 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache
Similar Organizations
AccuTheranostics
AccuTheranostics is a biotechnology company focused on the business of individualizing chemotherapy for cancer patients.
Arima Genomics
Arima Genomics is a biotechnology company that develops solutions to drive genomics discovery.
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Genocea Biosciences
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies.
Current Advisors List
Board_member
Advisor
Board_member
2009-01-01
Advisor
Advisor
Advisor
Advisor
Advisor
Current Employees Featured
Paul Tebbey SVP, Product Development & Portfolio Strategy @ Heat Biologics
SVP, Product Development & Portfolio Strategy
2021-09-01
Jeff Wolf Founder and CEO @ Heat Biologics
Founder and CEO
2011-05-01
Anil K. Goyal Vice President, Business Development @ Heat Biologics
Vice President, Business Development
Melissa Price Vice President of Clinical and Regulatory Affairs @ Heat Biologics
Vice President of Clinical and Regulatory Affairs
Matt Czajkowski Chief Financial Officer @ Heat Biologics
Chief Financial Officer
Jeff Hutchins Chief Scientific and Operating Officer @ Heat Biologics
Chief Scientific and Operating Officer
Vadim V. Deyev Director of Applied Research @ Heat Biologics
Director of Applied Research
Stanley Kim General Counsel @ Heat Biologics
General Counsel
Sandra Silberman Chief Medical Officer @ Heat Biologics
Chief Medical Officer
George Peoples Chief Medical Advisor @ Heat Biologics
Chief Medical Advisor
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-12-21 | Elusys Therapeutics | Elusys Therapeutics acquired by Heat Biologics | N/A |
Investors List
Square 1 Bank
Square 1 Bank investment in Post-IPO Debt - Heat Biologics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-06 | Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy |
Official Site Inspections
http://www.heatbio.com Semrush global rank: 4 M Semrush visits lastest month: 3.1 K
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 15.197.148.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Heat Biologics"
Scorpius Holdings - Crunchbase Company Profile & Funding
Contact Email info@heatbio.com Phone Number 9192407540 Scorpius Holdings is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen …See details»
Heat Biologics - Wikipedia
In 2008, Heat Biologics was founded by Jeff Wolf and Eckhard Podack, in conjunction with the University of Miami and Seed-One Ventures. The company relocated to North Carolina in 2011. NCBiotech provided $225,000 of initial funding the same year. On July 24, 2013, Heat Biologics stock went public on NASDAQ under ticker symbol HTBX. In 2017, Heat Biologics acquired an 80% controlling interest in Pelican Therapeutics. See details»
Heat Biologics Company Overview, Contact Details & Competitors …
Aug 16, 2024 Heat Biologics. Biotechnology Research United States 51-200 Employees. Scorpius Holdings Inc. through its Scorpius BioManufacturing subsidiary, is an integrated …See details»
Heat Biologics Completes Name Change to NightHawk
DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company …See details»
Heat Biologics’ Scorpion Subsidiary Announces Planned …
Apr 18, 2022 For more information, please visit: www.heatbio.com, ... plans to operate as a full-service Contract Development and Manufacturing Organization (CDMO) to provide third-party …See details»
What’s In a Name? Heat Biologics To Become NightHawk …
Apr 25, 2022 Heat Biologics has hit upon a new name that it says is a better reflection of its recent growth and evolution as a company.. The Morrisville-based clinical stage …See details»
www.heatbio.com
Www.heatbio.comSee details»
Heat Biologics - Overview, News & Similar companies - ZoomInfo
May 3, 2022 Heat Biologics contact info: Phone number: (919) 240-7133 Website: www.heatbio.com What does Heat Biologics do? Heat Biologics, Inc., a biopharmaceutical …See details»
Heat Biologics - VentureRadar
"Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune …See details»
Heat Biologics Announces Planned Name Change to NightHawk
DURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel …See details»
Heat Biologics’ Announces Planned Investor and Media Livestream …
DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in …See details»
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing …
Mar 25, 2022 New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular …See details»
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing …
Mar 25, 2022 For more information, please visit: www.heatbio.com, and also follow us on ... the capabilities helping position Scorpion as a leading contract development and manufacturing …See details»
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery
Aug 26, 2021 Developing a new era of precision medicines using a unique and proprietary drug discovery platform. August 26, 2021 08:00 ET | Source: Heat BiologicsSee details»
Heat Biologics Completes Name Change to NightHawk …
DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company …See details»
Heat Biologics to Provide Corporate Update
Aug 30, 2021 Conference call scheduled for September 2nd at 11:00 AM ET. DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a …See details»
Heat Biologics Announces Planned Transfer to the NYSE
DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class …See details»
Heat Biologics to Provide Corporate Update - GlobeNewswire
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class …See details»
Heat Biologics, Inc. to Present at the 13th Annual BIO Investor …
Sep 30, 2014 Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will be …See details»
Heat Biologics to Present at 2021 BIO CEO & Investor Digital …
Feb 12, 2021 DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in …See details»